Latest

Novo Nordisk "wins by volume": High-dose semaglutide trial shows 19% weight loss effect, but still lags behind Lilly’s competing product.

Novo Nordisk "wins by volume": High-dose semaglutide trial shows 19% weight loss effect, but still lags behind Lilly’s competing product.

``` Recently, Novo Nordisk announced results of a clinical trial, showing that its much-anticipated Semaglutide demonstrated more significant weight loss effects when the dosage was tripled. Semaglutide is Novo Nordisk’s flagship product, marketed under the brands Wegovy for weight loss and Ozempic for diabetes. In two recent phase 3 clinical
Admin